← back to search

Kei‐ichiro Arimoto

University of California San Diego · US
Area of research
Immunology · Oncology
Research interest
Research interests include interferon and immune responses, Cytokine Signaling Pathways and Interactions, Immune Response and Inflammation, and SARS-CoV-2 and COVID-19 Research.
h-index
18
citations
1,693
works
42
NIH funding
primary concept
email

Recent publications

Emerging role of immunogenic cell death in cancer immunotherapy
Frontiers in Immunology 2024cited by 70position: firstdoi
Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis
Nature Communications 2023cited by 74position: firstdoi
Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18
Cell Reports 2023cited by 25position: middledoi
Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell–Mediated Tumor Killing
Cancer Discovery 2020cited by 67position: middledoi
Negative regulation of type I IFN signaling
Journal of Leukocyte Biology 2018cited by 115position: firstdoi
STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling
Nature Structural & Molecular Biology 2017cited by 201position: firstdoi
Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation
Proceedings of the National Academy of Sciences 2015cited by 64position: middledoi
Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN‐λ and elevated secretion of Cxcl10
EMBO Molecular Medicine 2013cited by 114position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dong‐Er Zhang · University of California San Diego8 papers (2013–2024)Sayuri Miyauchi · UC San Diego Health System6 papers (2017–2024)Jun-Bao Fan · University of California San Diego5 papers (2015–2023)Ming Yan · The University of Melbourne4 papers (2015–2023)Mengdan Liu · University of California San Diego3 papers (2023–2024)Christoph Burkart · aTyr Pharma (United States)3 papers (2013–2020)Balázs Győrffy · Royal Canadian Navy2 papers (2015–2020)Dan Liu · RMIT University2 papers (2015–2020)Xiuli Cong · Zhejiang Hospital1 papers (2013–2013)Amanda G Davis · University of California San Diego1 papers (2023–2023)Frédéric Colland · Novartis (Switzerland)1 papers (2017–2017)Yu Zhou · Yangtze University1 papers (2020–2020)Hua Cheng · Harvard University1 papers (2020–2020)Huizhong Xu · Soochow University1 papers (2020–2020)Jeremy N. Rich · University of North Carolina at Chapel Hill1 papers (2020–2020)Stephan Wilmes · University of Dundee1 papers (2017–2017)Sergei V. Kotenko · Rutgers, The State University of New Jersey1 papers (2013–2013)Yi-Jou Huang · National Taiwan University1 papers (2023–2023) · 1 papers (2017–2017)Klaus‐Peter Knobeloch · University of Freiburg1 papers (2020–2020)